

SCIENTIFIC REPORTS

OPEN

Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic *db/db* mice

Linda A. Gallo, Micheal S. Ward, Amelia K. Fotheringham, Aowen Zhuang, Danielle J. Borg, Nicole B. Flemming, Ben M. Harvie, Toni L. Kinneally, Shang-Ming Yeh, Domenica A. McCarthy, Hermann Koepsell, Volker Vallon, Carol Pollock, Usha Panchapakesan & Josephine M. Forbes

Scientific Reports 6:26428; doi: 10.1038/srep26428; published online 26 May 2016; updated 07 July 2016

This Article contains errors in the Acknowledgements section.

“The authors acknowledge funding support from the National Health and Medical Council of Australia (1004926).”

should read:

“The authors acknowledge funding support from the National Health and Medical Research Council of Australia (1004926) and Diabetes Australia.”



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>